Altimmune (ALT) Liabilities and Shareholders Equity (2010 - 2026)

Altimmune (ALT) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $335.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 113.42% year-over-year to $335.6 million; the TTM figure through Mar 2026 stood at $1.0 billion (up 65.81% YoY), while the FY2025 annual figure was $279.9 million, up 100.95% from the prior year.
• Liabilities and Shareholders Equity improved to $335.6 million in Q1 2026 per ALT's latest filing, from $279.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $335.6 million in Q1 2026 and bottomed at $139.3 million in Q4 2024.
• Historically, Liabilities and Shareholders Equity has averaged $201.5 million across 5 years, with a median of $190.4 million in 2025.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity sank 33.87% — and 2026, when it soared 113.42%.
• Altimmune's Liabilities and Shareholders Equity stood at $206.9 million in 2022, then advanced by 1.79% to $210.6 million in 2023, then plunged by 33.87% to $139.3 million in 2024, then jumped by 100.95% to $279.9 million in 2025, then climbed by 19.9% to $335.6 million in 2026.
• Business Quant data shows ALT's Liabilities and Shareholders Equity at $335.6 million in Q1 2026, $279.9 million in Q4 2025, and $218.4 million in Q3 2025.